GTHX Company Profile and Key Details
G1 Therapeutics, Inc.
GTHX Stock Price Chart
Stock Price Today
G1 Therapeutics, Inc. (GTHX) stock surged +0.14%, trading at $7.16 on NASDAQ, up from the previous close of $7.15. The stock opened at $7.15, fluctuating between $7.14 and $7.16 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
Research Triangle Park, NC 27709
United States
Website: https://www.g1therapeutics.comContact: 919 213 9835About Company
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Company Information
| Employees | 100 |
| Beta | 1.68 |
| Sales or Revenue | $82.51M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
G1 Therapeutics, Inc. (NASDAQ: GTHX) stock price is $7.16 in the last trading session. During the trading session, GTHX stock reached the peak price of $7.16 while $7.14 was the lowest point it dropped to. The percentage change in GTHX stock occurred in the recent session was 0.14% while the dollar amount for the price change in GTHX stock was $0.01.
The NASDAQ listed GTHX is part of Biotechnology industry that operates in the broader Healthcare sector. G1 Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. James Stillman Hanson
Gen. Counsel & Corporation Sec.
Mr. Evan Hicks M.B.A.
Vice President of Marketing
Mr. William C. Roberts
Vice President of Investor Relations & Corporation Communications
Mr. Mark Avagliano
Chief Bus. Officer
Mr. John E. Bailey Jr.
Chief Executive Officer, Pres & Director
Ms. Jennifer K. Moses CPA
Chief Financial Officer
Dr. Mark A. Velleca M.D., Ph.D.
Senior Advisor & Director
Dr. Jay C. Strum Ph.D.
Chief Scientific Officer
Mr. Andrew Perry
Chief Commercial Officer
Ms. Monica Thomas
Gen. Counsel & Chief Compliance Officer
Mr. John W. Umstead V
Chief Financial Officer
Ms. Jennifer K. Moses C.P.A.
Chief Financial Officer
Dr. Rajesh K. Malik Ch.B., M.B., M.D.
Chief Medical Officer
Mr. Terry L. Murdock
Chief Operating Officer
Ms. Monica R. Thomas
Gen. Counsel & Chief Compliance Officer
Mr. Alexander D. Smith M.S.
Consultant
GTHX's closing price is 562.96% higher than its 52-week low of $1.08 where as its distance from 52-week high of $7.19 is -0.42%.
Number of GTHX employees currently stands at 100.
Official Website of GTHX is: https://www.g1therapeutics.com
GTHX could be contacted at phone 919 213 9835 and can also be accessed through its website. GTHX operates from 700 Park Offices Drive, Research Triangle Park, NC 27709, United States.
GTHX stock volume for the day was 1.1M shares. The average number of GTHX shares traded daily for last 3 months was 2.23M.
The market value of GTHX currently stands at $377.75M with its latest stock price at $7.16 and 52.76M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com